ポリクローナル抗体の世界市場：2025年～2033年

世界のポリクローナル抗体市場は、2024年に13億2,000万米ドルに達し、2033年までには21億7,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは5.9%で成長する見込みです。

ポリクローナル抗体はしばしばpAbsと略され、抗原に反応して様々なB細胞クローンによって産生される抗体の異種混合物と定義されます。この多様性は、pAbsが同じ抗原上の異なるエピトープを認識し結合することができる複数の免疫グロブリン分子から構成されていることを意味します。

単一のB細胞クローンに由来し、特定のエピトープを標的とするモノクローナル抗体とは異なり、ポリクローナル抗体は複数のB細胞系列から生成されます。その結果、結合能力の範囲が広がり、抗原上の複数の部位と相互作用することが可能になります。様々なエピトープに結合できるpAbsの能力は、抗原を検出する際の感度を高めます。この特性は、正確な検出が重要な研究・診断用途において特に有用です。

ポリクローナル抗体は、多くの科学的および臨床的用途、特に複数のエピトープに結合する能力が検出感度と信頼性を著しく向上させるイムノアッセイにおいて極めて重要です。その多様な結合特性により、ポリクローナル抗体は研究者にとっても臨床医にとっても不可欠なツールとなっており、診断や治療開発の進歩に重要な役割を果たしています。これらの要因が、世界のポリクローナル抗体市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

抗体生産技術の革新

世界のポリクローナル抗体市場は、抗体生産技術の革新によって大きく形成されています。これらの進歩は、抗体生産の効率、品質、拡張性を向上させ、研究、診断、治療用途における需要の増大に対応するために不可欠です。

抗体生産技術の革新には、渡辺武教授が開発した人工リンパ節技術が含まれます。人工リンパ節（aLN）は、抗原特異的免疫細胞のみを含むように設計されています。このリンパ節を免疫不全マウスに移植すると、従来の方法よりも10倍から100倍高い抗体価を産生することができます。この技術革新により、ポリクローナル抗体の収量が大幅に増加し、生産効率とコスト効率が向上しました。免疫反応のための制御された環境を作り出す能力は、高品質の抗体を迅速に生産する新たな道を開きます。

シングルB細胞テクノロジー技術により、目的の抗体を産生する個々のB細胞を効率的に分離することができます。単離の際に軽鎖と重鎖のペアを保存することにより、研究者は特異性の高いモノクローナル抗体を迅速に作製することができます。この方法は生産を迅速化するだけでなく、出来上がった抗体の特異性と有効性を高め、治療用としてより効果的なものにします。

抗体の設計とヒト化プロセスにおける人工知能の統合により、抗体の構造を最適化してその有効性を向上させることができます。この技術革新により、二重特異性抗体（bsAbs）やFc融合タンパク質のような新規の抗体誘導体の創製が容易になり、複雑な疾患の治療において治療の可能性が高まり、応用範囲が広がります。

さらに、業界の主要企業は、この世界のポリクローナル抗体市場を牽引する革新的な製品を発表しています。例えば、2023年2月、Rocheは脳腫瘍の診断と治療を強化する2つの重要な抗体を発表しました：IDH1 R132H（MRQ-67）Rabbit Monoclonal Primary AntibodyとATRX Rabbitポリクローナル抗体です。これらの抗体は、脳腫瘍、特に成人の悪性脳腫瘍の中で最も一般的なグリオーマの患者の変異を検出するために特別に設計されています。これらすべての要因が、世界のポリクローナル抗体市場に需要をもたらしています。

さらに、標的治療に対する需要の高まりが、ポリクローナル抗体の世界市場拡大に寄与しています。

高い生産コスト

世界のポリクローナル抗体市場はいくつかの課題に直面しており、中でも最も重要な課題の1つは生産コストの高さです。この要因は市場力学に大きな影響を与え、これらの重要な生物学的ツールへのアクセスや需要に影響を及ぼす可能性があります。

ポリクローナル抗体の生産には通常、ウサギ、ヤギ、ヒツジなどの動物を免疫する必要があります。動物の世話、飼育、ワクチン接種プロトコールに関連するコストは相当なものになります。これらの動物に適した環境を維持するためには、餌代、ヘルスケア、施設管理に継続的な費用がかかります。例えば、動物への予防接種の初期費用や、その後のブースター注射の費用は、すぐにかさみます。これらの要因が積み重なる結果、ポリクローナル抗体の価格は、モノクローナル抗体などの他の代替品に比べて高くなります。例えば、モノクローナル抗体は1ユニットあたり6,000米ドルから15,000米ドルであるのに対し、ポリクローナル抗体は一般的に低コストで製造されますが、それでも上記の要因から、購入しやすい価格という課題に直面しています。

生産コストの高さは、世界のポリクローナル抗体市場における大きな抑制要因となっています。それはメーカーの価格戦略だけでなく、研究者や臨床医がこれらの重要なツールを利用しやすいかどうかにも影響します。生産技術やプロセスの革新を通じてこうしたコスト課題に対処することは、市場の成長を高め、様々な分野でのポリクローナル抗体の応用を拡大する上で極めて重要です。生産を合理化し、コストを削減する方法を見出すことで、利害関係者は研究や臨床の場においてこれらの重要なリソースへのアクセスを改善することができます。このように、上記の要因は世界のポリクローナル抗体市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 抗体生産技術の革新
  • 抑制要因
    • 生産コストが高い
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品別

• 一次抗体
• 一次抗体
• 二次抗体

第7章 ソース別

• ウサギ
• ヤギ
• 羊
• その他

第8章 用途別

• 研究
• 診断
• その他

第9章 エンドユーザー別

• 病院・診断センター
• 学術・研究センター
• 製薬・バイオテクノロジー企業

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Abcam Limited.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• BioLegend, Inc.
• F. Hoffmann-La Roche Ltd
• GenScript
• Agilent Technologies, Inc
• Abnova Corporation.
• Good Biotech Corp.
• Rockland Immunochemicals, Inc.
• GeneTex, Inc.
• Innovagen AB

第13章 付録

The global polyclonal antibody market reached US$ 1.32 billion in 2024 and is expected to reach US$ 2.17 billion by 2033, growing at a CAGR of 5.9 % during the forecast period 2025-2033.

Polyclonal antibodies, often abbreviated as pAbs, are defined as a heterogeneous mixture of antibodies produced by various B-cell clones in response to an antigen. This diversity means that pAbs consist of multiple immunoglobulin molecules capable of recognizing and binding to different epitopes on the same antigen.

Unlike monoclonal antibodies, which are derived from a single B-cell clone and target a specific epitope, polyclonal antibodies are generated from multiple B-cell lineages. This results in a broader range of binding capabilities, allowing them to interact with multiple sites on the antigen. The ability of pAbs to bind to various epitopes enhances their sensitivity in detecting antigens. This characteristic is particularly valuable in research and diagnostic applications where precise detection is crucial.

Polyclonal antibodies are crucial in numerous scientific and clinical applications, especially in immunoassays, where their capacity to bind to multiple epitopes significantly enhances detection sensitivity and reliability. Their diverse binding properties make them indispensable tools for both researchers and clinicians, playing a key role in advancing diagnostics and therapeutic development. These factors have driven the global polyclonal antibody market expansion.

Market Dynamics: Drivers & Restraints

Innovations in Antibody Production Technologies

The global polyclonal antibody market is significantly shaped by innovations in antibody production technologies. These advancements enhance the efficiency, quality, and scalability of antibody production, which is essential for addressing the growing demand in research, diagnostics, and therapeutic applications.

Innovations in antibody production technologies include artificial lymph node technology developed by Professor Takeshi Watanabe, artificial lymph nodes (aLNs) are engineered to contain only antigen-specific immune cells. When implanted into immunodeficient mice, these nodes can produce antibody titers that are 10 to 100 times higher than those generated by conventional methods. This innovation greatly increases the yield of polyclonal antibodies, making production more efficient and cost-effective. The ability to create a controlled environment for immune responses opens new avenues for producing high-quality antibodies rapidly.

Single B cell technology technology enables the efficient isolation of individual B cells that produce desired antibodies. By preserving the pairs of light and heavy chains during isolation, researchers can quickly generate highly specific monoclonal antibodies. This method not only expedites production but also enhances the specificity and efficacy of the resulting antibodies, making them more effective for therapeutic use.

The integration of artificial intelligence in antibody design and humanization processes allows for optimizing antibody structures to improve their efficacy. This innovation facilitates the creation of novel antibody derivatives such as bispecific antibodies (bsAbs) and Fc-fusion proteins, which have enhanced therapeutic potential and broader applications in treating complex diseases.

Furthermore, key players in the industry have innovative launches that would drive this global polyclonal antibody market. For instance, in February 2023, Roche introduced two significant antibodies to enhance the diagnosis and treatment of brain cancer: the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody. These antibodies are specifically designed to detect mutations in patients with brain tumors, particularly gliomas, which represent the most common type of malignant brain tumor in adults. All these factors demand the global polyclonal antibody market.

Moreover, the rising demand for the growth of growing demand for targeted therapies contributes to the global polyclonal antibody market expansion.

High Cost of Production

The global polyclonal antibody market faces several challenges, with one of the most significant being the high cost of production. This factor can significantly influence market dynamics, affecting accessibility and demand for these crucial biological tools.

Producing polyclonal antibodies typically involves immunizing animals such as rabbits, goats, or sheep. The costs associated with animal care, housing, and vaccination protocols can be substantial. Maintaining a suitable environment for these animals incurs ongoing expenses for food, healthcare, and facility management. For example, the initial costs of immunizing an animal and subsequent booster shots can add up quickly. The cumulative effect of these factors results in higher prices for polyclonal antibodies compared to other alternatives, such as monoclonal antibodies. For instance, while monoclonal antibodies can range from USD 6,000 to USD 15,000 per unit, polyclonal antibodies are generally produced at lower costs but still face challenges related to affordability due to the factors mentioned above.

The high cost of production is a significant restraint in the global polyclonal antibody market. It affects not only the pricing strategies of manufacturers but also the accessibility of these important tools for researchers and clinicians. Addressing these cost challenges through innovations in production technologies and processes will be crucial for enhancing market growth and expanding the application of polyclonal antibodies across various fields. By finding ways to streamline production and reduce costs, stakeholders can improve access to these vital resources in research and clinical settings. Thus, the above factors could be limiting the global polyclonal antibody market's potential growth.

Segment Analysis

The global polyclonal antibody market is segmented based on product, source, application, end-user, and region.

Product:

The secondary antibodies segment is expected to dominate the global polyclonal antibody market share

The secondary antibodies segment holds a major portion of the global polyclonal antibody market share and is expected to continue to hold a significant portion of the global polyclonal antibody market share during the forecast period.

Secondary antibodies are generated from multiple B-cell clones and are specifically designed to bind to the constant region (Fc region) of primary antibodies. Their main function is to amplify the signal produced by primary antibodies during different assays, thereby improving the detection of target antigens. When a primary antibody attaches to its specific antigen, it forms an immune complex. Secondary polyclonal antibodies recognize and bind to the Fc region of these primary antibodies. This interaction is crucial as it enables the detection of the antigen that the primary antibody targets.

The binding of multiple secondary antibodies to a single primary antibody results in signal amplification. Since secondary antibodies can attach to various epitopes on the primary antibody, this multi-binding capability significantly enhances the overall signal. For instance, in an enzyme-linked immunosorbent assay (ELISA), this amplification can greatly improve the sensitivity of antigen detection, allowing for better visualization and quantification.

Furthermore, key players in the industry have innovative product launches that would propel this segment's growth in the global polyclonal antibody market. For instance, in March 2023, Lunaphore, a Swiss life sciences company dedicated to advancing spatial biology, announced the launch of its secondary antibodies portfolio. This initiative is part of Lunaphore's broader mission to provide essential components that facilitate spatial biology research in laboratories around the world. The new portfolio includes secondary antibodies specifically designed to enhance the detection capabilities of primary antibodies used in various assays. By offering these secondary antibodies, Lunaphore aims to empower researchers to conduct successful spatial biology experiments with greater accuracy and reliability. These factors have solidified the segment's position in the global polyclonal antibody market.

Geographical Analysis

North America is expected to hold a significant position in the global polyclonal antibody market share

North America holds a substantial position in the global polyclonal antibody market and is expected to hold most of the market share.

The increasing incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders in North America drives demand for effective diagnostic tools and therapeutic interventions. Polyclonal antibodies play a crucial role in both diagnostics and treatment, further boosting their market presence. North America, particularly the United States, is home to a robust biotechnology sector that leads in research and development. This environment fosters innovation and facilitates the creation of new polyclonal antibody products. The presence of major biopharmaceutical companies and research institutions enhances the development and commercialization of these antibodies.

The region is characterized by significant healthcare expenditure, which supports extensive research activities and the adoption of advanced therapeutic solutions. Increased funding for healthcare initiatives enables more comprehensive research into polyclonal antibodies, driving demand in both clinical and diagnostic settings. North America has a well-established research infrastructure that includes state-of-the-art laboratories and access to cutting-edge technologies. This infrastructure allows for efficient antibody production and validation processes, making it easier for researchers to utilize polyclonal antibodies in their studies.

Furthermore, in the region, key player's strategies such as partnerships & collaborations would drive this global polyclonal antibody market growth. For instance, in October 2022, Absolute Biotech launched as a consolidated entity that merges several prominent antibody-focused brands from around the world. This new company is dedicated to providing a wide range of antibody reagents and services, with a particular emphasis on enhancing the value of existing antibodies, reagents, and kits. They achieve this through advanced processes such as annotation, validation, sequencing, engineering, and recombinant manufacturing in Boston. Thus, the above factors are consolidating the region's position as a dominant force in the global polyclonal antibody market.

Asia Pacific is growing at the fastest pace in the global polyclonal antibody market share

Asia Pacific holds the fastest pace in the global polyclonal antibody market and is expected to hold most of the market share.

The rising incidence of chronic diseases such as autoimmune disorders, cancer, and infectious diseases in the APAC region is a major driver for the polyclonal antibody market. As more individuals are diagnosed with these conditions, there is a growing demand for effective diagnostic and therapeutic solutions, including polyclonal antibodies.

There is a growing emphasis on personalized medicine in healthcare, which tailors treatments to individual patient needs. Polyclonal antibodies play a vital role in this approach, as they can be used to develop targeted therapies that improve treatment efficacy and patient outcomes. Increased investment in biotechnology and pharmaceutical research in countries like China and India is fostering innovation in the development of polyclonal antibodies. This funding supports advancements in antibody production technologies and facilitates the exploration of new therapeutic applications.

The improvement of healthcare infrastructure across the APAC region enhances access to advanced medical technologies and treatments. Countries such as India and South Korea are investing in state-of-the-art laboratories and research facilities, which support the growth of the polyclonal antibody market. Government initiatives aimed at promoting biotechnology and healthcare innovation are contributing to market growth. Policies that encourage research collaboration, provide funding for scientific studies, and streamline regulatory processes help create a favorable environment for the development of polyclonal antibodies.

Furthermore, in the region, key player's strategies such as partnerships & collaborations would drive this global polyclonal antibody market growth. For instance, in June 2024, the transfer of the mastitis detection technology from IIT Kanpur to Prompt Equipments marks a significant advancement in addressing a critical issue in the dairy industry: bovine mastitis. This collaboration leverages advanced immunoassay techniques, specifically through the development of a Lateral Flow Immunoassay Strip, which utilizes polyclonal antibodies to detect the presence of Staphylococcus aureus, a major bacterial contributor to mastitis. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global polyclonal antibody market.

Competitive Landscape

The major global players in the polyclonal antibody market include Thermo Fisher Scientific Inc., Abcam Limited., Merck KGaA, Bio-Rad Laboratories, Inc., BioLegend, Inc., F. Hoffmann-La Roche Ltd, GenScript, Agilent Technologies, Inc, Abnova Corporation., Good Biotech Corp., Rockland Immunochemicals, Inc., GeneTex, Inc., and Innovagen AB among others.

Key Developments

• In November 2024, Sanofi announced a substantial investment of €40 million in its Lyon Gerland bioproduction facility, aimed at strengthening its position in the field of immunology and enhancing its production capabilities. This investment will primarily focus on the development of Thymoglobulin, a polyclonal antibody essential for transplantation, and will also facilitate the localization of production for TZIELD, a treatment for type 1 diabetes.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global polyclonal antibody market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Source
• 3.3. Snippet by Application
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovations in Antibody Production Technologies
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Production
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 6.1.2. Market Attractiveness Index, By Product
• 6.2. Primary Antibodies*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Primary Antibodies
• 6.4. Secondary Antibodies

7. By Source

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 7.1.2. Market Attractiveness Index, By Source
• 7.2. Rabbits*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Goats
• 7.4. Sheep
• 7.5. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Research*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Diagnostics
• 8.4. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals & Diagnostic Centers*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Academic & Research Centers
• 9.4. Pharmaceutical & Biotechnology Companies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Thermo Fisher Scientific Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Abcam Limited.
• 12.3. Merck KGaA
• 12.4. Bio-Rad Laboratories, Inc.
• 12.5. BioLegend, Inc.
• 12.6. F. Hoffmann-La Roche Ltd
• 12.7. GenScript
• 12.8. Agilent Technologies, Inc
• 12.9. Abnova Corporation.
• 12.10. Good Biotech Corp.
• 12.11. Rockland Immunochemicals, Inc.
• 12.12. GeneTex, Inc.
• 12.13. Innovagen AB

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us